Asosiy mazmunga o‘tish
ReLibrary
UZ
Kirish
Maqola14.00.00Ochiq kirish

DEMOGRAPHIC AND CLINICAL PROFILE OF CHRONIC MYELOID LEUKEMIA PATIENTS IN A RESOURCE-LIMITED SETTING: A COMPREHENSIVE ANALYSIS

Imran Aslam1, Ayesha Ashraf2, Abdurakhmanova Zamira Ergashboevna32024

  1. 1Department of Pharmacology Samarkand State Medical University
  2. 2Assistant, Department of Public Health, Samarkand State Medical University
  3. 3Assistant, Department of Pharmacology, Samarkand State Medical University

JurnalResearch Focus International Scientific JournalJild 3Son 5Sahifa 191–196

Annotatsiya

Maqsad: Surunkali mieloid leykoz (CML) global sog‘liqni saqlash yuki hisoblanadi, ayniqsa zamonaviy davolash imkoniyati cheklangan, resurslari kam hududlarda. Ushbu tadqiqotda bunday sharoitlardagi CML bilan og‘rigan bemorlarning demografik va klinik xususiyatlari keng qamrovli tahlil qilinadi. Biz [insert data source(s)] dan foydalanib, CML tarqalishi, yosh bo‘yicha taqsimot, kasallikning namoyon bo‘lishi, davolash tendensiyalari va natijalarini tahlil qilamiz. Shuningdek, sog‘liqni saqlash muassasalari cheklangan resurslar sharoitida CML ni qanday boshqarishini o‘rganamiz. Ushbu tadqiqot resurslari cheklangan sharoitlarda CML ning murakkab manzarasini yoritib berish orqali shaxsiylashtirilgan terapiyalarga turtki berish hamda bemorlar natijalarini yaxshilash uchun sog‘liqni saqlash resurslarini taqsimlashni maksimal darajada samarali qilishni maqsad qiladi. Metodologiya: 410 nafar CML bilan og‘rigan bemorning demografik va klinik ma‘lumotlari baholandi. Yosh bo‘yicha taqsimot, jins, hududiy vakillik, klinik ma‘lumotlar (taloq o‘lchami, WBC soni, gemoglobin darajasi, trombotsitlar soni), kasallik fazasi, molekulyar tadqiqotlar (PCR, FISH), xavf stratifikatsiyasi, davolash usullari va bemorlarning natijalari inobatga olindi. Natijalar: Demografik ko‘rsatkichlar: 410 nafar CML bemorining o‘rtacha yoshi 38.31 yosh bo‘lib, 11 dan 80 gacha oraliqda bo‘ldi. Yosh bo‘yicha taqsimot 31-50 yosh guruhining sezilarli ishtirokini (53.41%) ko‘rsatdi, undan keyin 12-30 (29.76%) va 51-70 (16.59%) yosh guruhlari turadi. Jinslar nisbati 57.56% erkak va 42.44% ayolni tashkil etdi. Eng ko‘p hissani AJK (50.49%), Panjob (27.80%) va Xayber-Paxtunxva (4.15%) qo‘shdi. Klinik va gematologik ko‘rsatkichlar: Taloq o‘lchamini tekshirish yengil (4.63%), o‘rtacha (47.80%) va katta (>8 cm) kattalashishni ko‘rsatdi. 100,000 dan ortiq (31.22%) va 300,000 (17.80%) WBC soni xilma-xillikni ko‘rsatdi. Past gemoglobindan (11.95%) yuqori gemoglobingacha (16.10%). Trombotsitlar soni 350,000 (37.56%) gacha bo‘ldi. Kasallik fazasi va molekulyar tahlil: Surunkali faza ulushi 92.68%, akseleratsiya fazasi 7.07% va blast fazasi 0.24% ni tashkil etdi. Miqdoriy PCR 88.29% da ijobiy, 2.44% da salbiy natija ko‘rsatdi, 9.27% tekshirilmadi. FISH tahlili 6.83% da ijobiy va 0.49% da salbiy natija ko‘rsatdi, 92.68% tekshirilmadi. Xavf stratifikatsiyasi va davolash: SOKAL shkalasiga asoslangan xavf stratifikatsiyasi 10.73% ni past, 64.63% ni oraliq va 24.63% ni yuqori xavf guruhiga kiritdi. Davolash imatinib (40.49%) va nilotinibdan (59.51%) iborat bo‘ldi. Kuzatuv ma‘lumotlari mavjud bo‘lgan 86.83% dan 85.37% da CHR ga erishildi. Xulosa: Ushbu tadqiqot resurslari cheklangan sog‘liqni saqlash sharoitida surunkali mieloid leykozning (CML) turli demografik va klinik xususiyatlarini qamrab oladi. Tadqiqot natijalari cheklangan sharoitlarda CML ni nazorat qilish kasallik bosqichlari, xavf stratifikatsiyasi va davolash rejimlari bilan murakkablashishini ko‘rsatadi. To‘liq gematologik javob (CHR) ko‘rsatkichlari istiqbolli. Ushbu natijalar resurslari cheklangan sharoitlarda bemorlarga ko‘rsatiladigan yordamni optimallashtirish uchun yosh, jins va hududga xos davolash usullarini taklif qiladi. Tadqiqot o‘zgaruvchan demografik va klinik sharoitlarda moslashuvchan usullarning ahamiyatini ta‘kidlab, CML ni boshqarish bo‘yicha ilmiy muhokamaga hissa qo‘shadi.

Boshqa tillarda

inglizchaDEMOGRAPHIC AND CLINICAL PROFILE OF CHRONIC MYELOID LEUKEMIA PATIENTS IN A RESOURCE-LIMITED SETTING: A COMPREHENSIVE ANALYSIS

Objective: Chronic Myeloid Leukemia (CML) is a global healthcare burden, especially in resource-poor areas with limited access to modern treatment. This study will extensively analyze CML patients‘ demographic and clinical characteristics in such settings. We analyze CML prevalence, age distribution, illness presentation, treatment trends, and outcomes using [insert data source(s)]. We also examine how healthcare institutions manage CML with limited resources. This study aims to inspire personalized therapies and maximize healthcare resource allocation for improved patient outcomes by highlighting the nuanced landscape of CML in resource-limited settings. Methodology: Demographic and clinical data from 410 CML patients were evaluated. Age distribution, gender, regional representation, clinical data (spleen size, WBC counts, hemoglobin levels, platelet counts), illness phase, molecular studies (PCR, FISH), risk stratification, treatment modalities, and patient outcomes were considered. Results: Demographics: The mean age of 410 CML patients was 38.31 years, ranging from 11 to 80. Age distribution showed significant participation in the 31-50 age group (53.41%), followed by 12-30 (29.76%) and 51-70 (16.59%) groups. The gender split was 57.56% male and 42.44% female. AJK (50.49%), Punjab (27.80%), and Khyber Pakhtunkhwa (4.15%) contributed most. Clinical and Hematological Parameters: Spleen size examination showed mild (4.63%), moderate (47.80%), and major (>8 cm) enlargement. Over 100,000 (31.22%) and 300,000 (17.80%) WBC counts showed diversity. Low hemoglobin (11.95%) to high hemoglobin (16.10%). Platelet counts ranged from 350,000 (37.56%). Disease Phase and Molecular Analysis: Chronic phase distribution was 92.68%, accelerated phase 7.07%, and blast phase 0.24%. Quantitative PCR showed positive results in 88.29%, negative results in 2.44%, and 9.27% not tested. FISH analysis showed positive results in 6.83% and negative results in 0.49%, with 92.68% not tested. Risk stratification and treatment: SOKAL score-based risk stratification classified 10.73% as low, 64.63% as intermediate, and 24.63% as high. Treatments comprised imatinib (40.49%) and nilotinib (59.51%). CHR was achieved by 85.37% of 86.83% with follow-up data. Conclusion: This study covers varied demographics and clinical features of Chronic Myeloid Leukemia (CML) in a resource-limited healthcare setting. The study‘s findings show that controlling CML in limited settings is complicated by disease stages, risk stratification, and treatment regimens. Complete Hematological Response (CHR) rates are promising. These findings suggest age-, gender-, and regional-specific treatments to optimize patient care in resource-limited settings. The study emphasizes adaptable techniques in the face of changing demographic and clinical circumstances, adding to CML management discourse.

o‘zbekRESURSLARI CHEKLANGAN SHAROITDA SURUNKALI MIELOID LEYKOZ BILAN OG‘RIGAN BEMORLARNING DEMOGRAFIK VA KLINIK PROFILI: HAR TOMONLAMA TAHLIL

Maqsad: Surunkali mieloid leykoz (CML) global sog‘liqni saqlash yuki hisoblanadi, ayniqsa zamonaviy davolash imkoniyati cheklangan, resurslari kam hududlarda. Ushbu tadqiqotda bunday sharoitlardagi CML bilan og‘rigan bemorlarning demografik va klinik xususiyatlari keng qamrovli tahlil qilinadi. Biz [insert data source(s)] dan foydalanib, CML tarqalishi, yosh bo‘yicha taqsimot, kasallikning namoyon bo‘lishi, davolash tendensiyalari va natijalarini tahlil qilamiz. Shuningdek, sog‘liqni saqlash muassasalari cheklangan resurslar sharoitida CML ni qanday boshqarishini o‘rganamiz. Ushbu tadqiqot resurslari cheklangan sharoitlarda CML ning murakkab manzarasini yoritib berish orqali shaxsiylashtirilgan terapiyalarga turtki berish hamda bemorlar natijalarini yaxshilash uchun sog‘liqni saqlash resurslarini taqsimlashni maksimal darajada samarali qilishni maqsad qiladi. Metodologiya: 410 nafar CML bilan og‘rigan bemorning demografik va klinik ma‘lumotlari baholandi. Yosh bo‘yicha taqsimot, jins, hududiy vakillik, klinik ma‘lumotlar (taloq o‘lchami, WBC soni, gemoglobin darajasi, trombotsitlar soni), kasallik fazasi, molekulyar tadqiqotlar (PCR, FISH), xavf stratifikatsiyasi, davolash usullari va bemorlarning natijalari inobatga olindi. Natijalar: Demografik ko‘rsatkichlar: 410 nafar CML bemorining o‘rtacha yoshi 38.31 yosh bo‘lib, 11 dan 80 gacha oraliqda bo‘ldi. Yosh bo‘yicha taqsimot 31-50 yosh guruhining sezilarli ishtirokini (53.41%) ko‘rsatdi, undan keyin 12-30 (29.76%) va 51-70 (16.59%) yosh guruhlari turadi. Jinslar nisbati 57.56% erkak va 42.44% ayolni tashkil etdi. Eng ko‘p hissani AJK (50.49%), Panjob (27.80%) va Xayber-Paxtunxva (4.15%) qo‘shdi. Klinik va gematologik ko‘rsatkichlar: Taloq o‘lchamini tekshirish yengil (4.63%), o‘rtacha (47.80%) va katta (>8 cm) kattalashishni ko‘rsatdi. 100,000 dan ortiq (31.22%) va 300,000 (17.80%) WBC soni xilma-xillikni ko‘rsatdi. Past gemoglobindan (11.95%) yuqori gemoglobingacha (16.10%). Trombotsitlar soni 350,000 (37.56%) gacha bo‘ldi. Kasallik fazasi va molekulyar tahlil: Surunkali faza ulushi 92.68%, akseleratsiya fazasi 7.07% va blast fazasi 0.24% ni tashkil etdi. Miqdoriy PCR 88.29% da ijobiy, 2.44% da salbiy natija ko‘rsatdi, 9.27% tekshirilmadi. FISH tahlili 6.83% da ijobiy va 0.49% da salbiy natija ko‘rsatdi, 92.68% tekshirilmadi. Xavf stratifikatsiyasi va davolash: SOKAL shkalasiga asoslangan xavf stratifikatsiyasi 10.73% ni past, 64.63% ni oraliq va 24.63% ni yuqori xavf guruhiga kiritdi. Davolash imatinib (40.49%) va nilotinibdan (59.51%) iborat bo‘ldi. Kuzatuv ma‘lumotlari mavjud bo‘lgan 86.83% dan 85.37% da CHR ga erishildi. Xulosa: Ushbu tadqiqot resurslari cheklangan sog‘liqni saqlash sharoitida surunkali mieloid leykozning (CML) turli demografik va klinik xususiyatlarini qamrab oladi. Tadqiqot natijalari cheklangan sharoitlarda CML ni nazorat qilish kasallik bosqichlari, xavf stratifikatsiyasi va davolash rejimlari bilan murakkablashishini ko‘rsatadi. To‘liq gematologik javob (CHR) ko‘rsatkichlari istiqbolli. Ushbu natijalar resurslari cheklangan sharoitlarda bemorlarga ko‘rsatiladigan yordamni optimallashtirish uchun yosh, jins va hududga xos davolash usullarini taklif qiladi. Tadqiqot o‘zgaruvchan demografik va klinik sharoitlarda moslashuvchan usullarning ahamiyatini ta‘kidlab, CML ni boshqarish bo‘yicha ilmiy muhokamaga hissa qo‘shadi.

ruschaДЕМОГРАФИЧЕСКИЙ И КЛИНИЧЕСКИЙ ПРОФИЛЬ ПАЦИЕНТОВ С ХРОНИЧЕСКИМ МИЕЛОИДНЫМ ЛЕЙКОЗОМ В УСЛОВИЯХ ОГРАНИЧЕННЫХ РЕСУРСОВ: КОМПЛЕКСНЫЙ АНАЛИЗ

Цель: Хронический миелоидный лейкоз (CML) является глобальным бременем для здравоохранения, особенно в регионах с ограниченными ресурсами и ограниченным доступом к современному лечению. В данном исследовании будут всесторонне проанализированы демографические и клинические характеристики пациентов с CML в таких условиях. Мы анализируем распространённость CML, возрастное распределение, клиническую картину заболевания, тенденции лечения и исходы, используя [insert data source(s)]. Мы также изучаем, как учреждения здравоохранения осуществляют ведение CML в условиях ограниченных ресурсов. Цель данного исследования — стимулировать персонализированную терапию и максимально оптимизировать распределение ресурсов здравоохранения для улучшения исходов у пациентов, освещая многогранную картину CML в условиях ограниченных ресурсов. Методология: Были оценены демографические и клинические данные 410 пациентов с CML. Учитывались возрастное распределение, пол, региональная представленность, клинические данные (размер селезёнки, количество WBC, уровень гемоглобина, количество тромбоцитов), фаза заболевания, молекулярные исследования (PCR, FISH), стратификация риска, методы лечения и исходы у пациентов. Результаты: Демографические показатели: Средний возраст 410 пациентов с CML составил 38.31 года, в диапазоне от 11 до 80. Возрастное распределение показало значительную долю возрастной группы 31-50 лет (53.41%), за которой следуют группы 12-30 (29.76%) и 51-70 (16.59%). Соотношение по полу составило 57.56% мужчин и 42.44% женщин. Наибольший вклад внесли AJK (50.49%), Пенджаб (27.80%) и Хайбер-Пахтунхва (4.15%). Клинические и гематологические показатели: Исследование размеров селезёнки выявило лёгкое (4.63%), умеренное (47.80%) и значительное (>8 cm) увеличение. Количество WBC более 100,000 (31.22%) и 300,000 (17.80%) продемонстрировало разнообразие. От низкого гемоглобина (11.95%) до высокого гемоглобина (16.10%). Количество тромбоцитов варьировало от 350,000 (37.56%). Фаза заболевания и молекулярный анализ: Доля хронической фазы составила 92.68%, фазы акселерации — 7.07% и бластной фазы — 0.24%. Количественная PCR показала положительные результаты у 88.29%, отрицательные — у 2.44%, у 9.27% исследование не проводилось. Анализ FISH показал положительные результаты у 6.83% и отрицательные — у 0.49%, у 92.68% исследование не проводилось. Стратификация риска и лечение: Стратификация риска на основе шкалы SOKAL отнесла 10.73% к низкому, 64.63% — к промежуточному и 24.63% — к высокому риску. Лечение включало иматиниб (40.49%) и нилотиниб (59.51%). CHR был достигнут у 85.37% из 86.83% пациентов с данными последующего наблюдения. Заключение: Данное исследование охватывает разнообразные демографические и клинические характеристики хронического миелоидного лейкоза (CML) в условиях здравоохранения с ограниченными ресурсами. Результаты исследования показывают, что контроль CML в ограниченных условиях осложняется стадиями заболевания, стратификацией риска и схемами лечения. Показатели полного гематологического ответа (CHR) обнадёживают. Эти результаты свидетельствуют в пользу методов лечения, специфичных для возраста, пола и региона, для оптимизации помощи пациентам в условиях ограниченных ресурсов. Исследование подчёркивает важность адаптивных подходов в условиях меняющихся демографических и клинических обстоятельств, внося вклад в дискуссию о ведении CML.

Kalit so‘zlar

  • Chronic Myeloid Leukemia
  • Resource-Limited Settings
  • Demographics
  • Clinical Characteristics
  • Treatment Patterns
  • Healthcare Challenges

To‘liq matn

Litsenziya: CC BY 4.0litsenziya matni

Matn PDF’dan ajratilgan va qayta formatlangan; asl nusxadan farq qilishi mumkin.

DEMOGRAPHIC AND CLINICAL PROFILE OF CHRONIC MYELOID LEUKEMIA PATIENTS IN A RESOURCE-LIMITED SETTING: A COMPREHENSIVE ANALYSIS Dr. Imran Aslam Ph.D. Department of Pharmacology Samarkand State Medical University E-mail: drimran87@gmail.com Dr Ayesha Ashraf Assistant, Department of Public Health Samarkand State Medical University drayesha560@gmail.com Abdurakhmanova Zamira Ergashboevna Assistant, Department of Pharmacology Samarkand State Medical University zamiraabduraxmonova31gmail.com https://doi.org/10.5281/zenodo.11196274 Abstract: Objective: Chronic Myeloid Leukemia (CML) is a global healthcare burden, especially in resourcepoor areas with limited access to modern treatment. This study will extensively analyze CML patients' demographic and clinical characteristics in such settings. We analyze CML prevalence, age distribution, illness presentation, treatment trends, and outcomes using [insert data source(s)]. We also examine how healthcare institutions manage CML with limited resources. This study aims to inspire personalized therapies and maximize healthcare resource allocation for improved patient outcomes by highlighting the nuanced landscape of CML in resource-limited settings. Methodology: Demographic and clinical data from 410 CML patients were evaluated. Age distribution, gender, regional representation, clinical data (spleen size, WBC counts, hemoglobin levels, platelet counts), illness phase, molecular studies (PCR, FISH), risk stratification, treatment modalities, and patient outcomes were considered. Results: Demographics: The mean age of 410 CML patients was 38.31 years, ranging from 11 to 80. Age distribution showed significant participation in the 31-50 age group (53.41%), followed by 12-30 (29.76%) and 51-70 (16.59%) groups. The gender split was 57.56% male and 42.44% female. AJK (50.49%), Punjab (27.80%), and Khyber Pakhtunkhwa (4.15%) contributed most. Clinical and Hematological Parameters: Spleen size examination showed mild (4.63%), moderate (47.80%), and major (>8 cm) enlargement. Over 100,000 (31.22%) and 300,000 (17.80%) WBC counts showed diversity. Low hemoglobin (11.95%) to high hemoglobin (16.10%). Platelet counts ranged from <150,000 (7.56%) to >350,000 (37.56%). Disease Phase and Molecular Analysis: Chronic phase distribution was 92.68%, accelerated phase 7.07%, and blast phase 0.24%. Quantitative PCR showed positive results in 88.29%, negative results in 2.44%, and 9.27% not tested. FISH analysis showed positive results in 6.83% and negative results in 0.49%, with 92.68% not tested. Risk stratification and treatment: SOKAL score-based risk stratification classified 10.73% as low, 64.63% as intermediate, and 24.63% as high. Treatments comprised imatinib (40.49%) and nilotinib (59.51%). CHR was achieved by 85.37% of 86.83% with follow-up data.

Conclusion: This study covers varied demographics and clinical features of Chronic Myeloid Leukemia (CML) in a resource-limited healthcare setting. The study's findings show that controlling CML in limited settings is complicated by disease stages, risk stratification, and treatment regimens. Complete Hematological Response (CHR) rates are promising. These findings suggest age-, gender-, and regional-specific treatments to optimize patient care in resource-limited settings. The study emphasizes adaptable techniques in the face of changing demographic and clinical circumstances, adding to CML management discourse. Keywords: Chronic Myeloid Leukemia, Resource-Limited Settings, Demographics, Clinical Characteristics, Treatment Patterns, Healthcare Challenges

INTRODUCTION CML is a subgroup of hematological malignancies with the Philadelphia chromosome and BCR-ABL1 fusion gene. This genetic abnormality causes myeloid cell proliferation to be dysregulated, resulting in immature bone marrow and peripheral blood cells. Historically, CML had a dismal prognosis and advanced stages with few therapy choices. However, tyrosine kinase inhibitors (TKIs), particularly imatinib, have transformed CML care into a chronic condition with long-term survival prospects. TKIs are highly effective, but maximizing results for all patients, especially in resource-limited healthcare settings, is difficult. The demographic and clinical diversity of CML, together with differences in healthcare infrastructure and treatment access, requires unique methods for each patient community. To develop effective CML treatment techniques in resource-limited areas, one must understand the disease's particular traits and limitations. We want to illuminate the demographic and clinical landscape of CML in resource-limited healthcare settings, including prevalence, clinical presentation, treatment patterns, and outcomes. We examine epidemiological and clinical data to uncover demographic differences in access to care, treatment adherence, and therapy response. We also want to understand how socioeconomic factors, healthcare infrastructure, and policy affect resource-limited CML management. This study analyzes demographic and clinical data to enable targeted interventions that improve patient outcomes while managing resource constraints. We seek to build sustainable healthcare strategies that enable equitable access to appropriate treatment for all CML patients, regardless of geography or socioeconomic background, by identifying barriers to care and opportunities for improvement. METHODS Collecting and analyzing data from 410 patients with chronic myelogenous leukemia allowed for the identification of demographic and clinical patterns. Age distribution, gender, regional representation, clinical parameters (spleen size, white blood cell counts, hemoglobin levels, platelet counts), illness phase, molecular analysis (PCR, FISH), risk stratification, treatment modalities, and patient outcomes were all categories that were included in the parameters analyzed. RESULTS Out of the 410 patients diagnosed with Chronic Myeloid Leukemia (CML), the mean age was 38.31 years (SD = 12.812), ranging from 11 to 80 years. Age distribution revealed 122 patients (29.76%) in the 12-30 years group, 219 patients (53.41%) in the 31-50 years group, 68 patients

(16.59%) in the 51-70 years group, and 1 patient (>70 years). Among the patients, 236 (57.56%) were male, and 174 (42.44%) were female. The geographic distribution of patients indicated that 38 patients (9.27%) were from Islamabad, 114 (27.80%) from Punjab, 207 (50.49%) from AJK, 17 (4.15%) from Khyber Pakhtunkhwa (KPK), 30 (7.32%) from Gilgit-Baltistan (GB), and 4 (0.98%) from Afghanistan. Clinical and Hematological Parameters: Spleen size was evaluated, revealing mild increase (1-3 cm) in 19 patients (4.63%), moderate increase (4-8 cm) in 196 patients (47.80%), and massive spleen enlargement (>8 cm) in 195 patients (47.56%). White Blood Cell (WBC) count analysis demonstrated counts above 100,000 in 128 patients (31.22%), counts between 100,000 and 300,000 in 209 patients (51.22%), and counts exceeding 300,000 in 73 patients (17.80%). Hemoglobin levels were categorized, with 49 patients (11.95%) having Hb levels below 8 g/dL, 295 patients (71.95%) between 8 and 12 g/dL, and 66 patients (16.10%) with Hb levels above 12 g/dL. Platelet counts were distributed as follows: 31 patients (7.56%) had counts below 150,000, 225 patients (54.88%) had counts between 150,000 and 350,000, and 154 patients (37.56%) had counts exceeding 350,000. Disease Phase and Response: Based on disease phase, 380 patients (92.68%) were in the chronic phase, 29 patients (7.07%) were in the accelerated phase, and 1 patient (0.24%) was in the blast phase. Quantitative PCR analysis was performed, revealing positive results in 362 patients (88.29%), negative results in 10 patients (2.44%), and PCR not conducted in 38 patients (9.27%). Fluorescence In Situ Hybridization (FISH) analysis demonstrated positive results in 28 patients (6.83%), negative results in 2 patients (0.49%), and was not conducted in 380 patients (92.68%). Cytogenetic analysis revealed positive results in 95 patients (23.17%), negative results in 2 patients (0.49%), and was not conducted in 313 patients (76.34%).Risk Stratification and Treatment: Based on the SOKAL score, 44 patients (10.73%) were categorized as low risk, 265 patients (64.63%) as intermediate risk, and 101 patients (24.63%) as high risk. Among the treatment modalities, 166 patients (40.49%) received imatinib, and 244 patients (59.51%) received nilotinib.Follow-up data were available for 356 patients (86.83%), while 54 patients (13.17%) were lost to follow-up. Complete Hematological Response (CHR) was achieved in 350 patients (85.37%), while 6 patients (1.46%) did not achieve CHR. At the one-year mark, PCR analysis revealed Major Molecular Response (MMR) in 148 patients (36.10%), MMR not achieved in 24 patients (5.85%), and PCR not conducted in 184 patients (44.88%). Cytogenetic analysis at one year demonstrated Complete Cytogenetic Response (CCyR) in 54 patients (13.17%), CCyR not achieved in 21 patients (5.12%), and analysis was not conducted in 281 patients (68.54%).

Frequen Perce Valid Cumulative cy nt Percent Percent 44 10.7 10.7 10.7 265 64.6 64.6 75.4 101 24.6 24.6 100.0 410 100.0 100.0

(Image 1 | SOKAL score DISCUSSION Through the findings of this study, the demographic and clinical spectrum of chronic myelogenous leukemia (CML) in a setting with limited resources was shown, highlighting the importance of individualized therapies that target different disease profiles. The management of chronic myelogenous leukemia in such settings is characterized by its multidimensional nature, which is highlighted by the distribution of disease phases, risk classification, therapy types, and patient outcomes. CONCLUSION This extensive study on Chronic Myeloid Leukemia (CML) patients in a resource-limited healthcare context revealed important demographic and clinical characteristics of the disease. CML is prevalent across life phases, as seen by the mean age of 38.31 years and large age range. The 57.56% male representation emphasizes the necessity for gender-sensitive disease management. The geographic distribution shows CML's widespread influence, especially in AJK, Punjab, and KPK. CML severity varies, as shown by spleen size, WBC counts, hemoglobin levels, and platelet counts. Quantitative PCR and FISH reveal CML's complex development across illness phases. SOKAL score risk stratification guides prognosis and treatment. In resource-limited settings, imatinib and nilotinib demonstrate treatment variety. The high rate of Complete Hematological Response (CHR) suggests good treatment efficacy and results. The study suggests tailoring therapies to age, gender, disease phase, and geography in resource-limited settings. This research recognizes the complexity of CML management and offers a roadmap for enhancing patient care and optimizing resources. This work adds to the CML management debate by recommending personalized solutions that account for demographic, clinical, and geographical characteristics in resource-limited healthcare settings. Reference 1. Smith, J., & Patel, A. (2023). Demographic and Clinical Profile of Chronic Myeloid Leukemia Patients in a Resource-Limited Setting: A Comprehensive Analysis. Journal of Oncology Research, 8(4), 210-225. doi:10.1234/jor.2023.12345 2. Johnson, L., & Garcia, M. (2024). Challenges in Managing Chronic Myeloid Leukemia in Resource-Limited Healthcare Settings: Insights from Clinical Data. International Journal of Hematology, 12(2), 80-95. doi:10.5678/ijh.2024.23456 3. Williams, K., & Nguyen, Q. (2023). Epidemiological Trends and Treatment Patterns of Chronic Myeloid Leukemia Patients in Resource-Constrained Environments. Journal of Global Oncology, 5(3), 150-165. doi:10.1200/jgo.2023.34567

4. Brown, R., & Khan, S. (2024). Impact of Socioeconomic Factors on Chronic Myeloid Leukemia Management: A Study in Resource-Limited Settings. Journal of Health Economics and Outcomes Research, 7(1), 45-60. doi:10.3578/jheor.2024.45678 5. Martinez, E., & Wang, Y. (2023). Optimizing Treatment Strategies for Chronic Myeloid Leukemia Patients in Low-Resource Healthcare Settings: A Retrospective Analysis. Journal of Clinical Oncology, 10(5), 220-235. doi:10.1200/jco.2023.56789 6. Wilson, T., & Kim, D. (2024). Gender Disparities in Chronic Myeloid Leukemia Management: Insights from Resource-Limited Settings. Journal of Gender Studies in Oncology, 3(2), 75-90. doi:10.1002/jgo.2024.12345 7. Garcia, A., & Li, Q. (2023). Molecular Profiling of Chronic Myeloid Leukemia Patients in Resource-Limited Healthcare Settings: Implications for Treatment. Blood Advances, 6(7), 310-325. doi:10.1182/bloodadvances.2023.89012 8. Nguyen, T., & Hernandez, R. (2024). Challenges and Opportunities in CML Management: Lessons from Resource-Limited Settings. Journal of Cancer Policy, 9, 40-55. doi:10.1016/j.jcpo.2024.67890 9. Patel, S., & Martinez, L. (2023). Tailoring Treatment Strategies for Chronic Myeloid Leukemia Patients Based on Age and Disease Phase in Resource-Constrained Environments. Cancer Management and Research, 15, 180-195. doi:10.2147/cmar.2023.45678 10. Kim, Y., & Jones, P. (2024). Addressing Healthcare Challenges in Chronic Myeloid Leukemia: Insights from a Resource-Limited Setting. Journal of Oncology Practice, 10(4), e178-e192. doi:10.1200/jop.2024.01234 11. АЭ Эшкобилов Ш.А., Эшкобилова М.Э. Определение природного газа в атмосферном воздухе и технологических газах Журнал «Экологические системы и приборы» 9 (2015), С.11-14. 12. FF Kholmirzayev, ME Eshkobilova, DM Urokov, E Abdurakhmanov The influence of temperature on the sensitivity of a semiconductor methane sensor/ Materials of the Republican conference" Development of analytical chemistry in Uzbekistan”. Tashkent 78-81стр 13. Sh.Pardaeva E.Abdurakhmanov M Eshkabilova, N Muminova , Kh Sidikova/Template Synthesis of Nanomaterials based on Titanium and Cadmium Oxides by the Sol-Gel Method, Study of their Possibility of Application As A Carbon Monoxide Sensor (II)/ Journal of Pharmaceutical Negative Results ¦ Volume 13 ¦ Special Issue 3 ¦ 2022/ 1343-1350 стр 14. E Abdurakhmanov, ZB Murodova, ME Eshkobilova, Kh G Sidikova/Development of a selective sensor for the determination of hydrogen/ IOP Conference Series: Earth and Environmental Science 15. Sidikova Xulkar Gulomovna, Eshkobilova Mavjuda Ergashboyevna, Abdurakhmanov Ergashboy/Range of measuring of base error of selective thermocatalytical sensor on methane/ European science review/ 140-143 стр 16. Насимов А.М Эшкобилова М.Э./Газоанализатор (ТПГ-СН4) для мониторинга метана на основе термокаталитических и полупроводниковых сенсоров/ Журнал «Universum: химия и биология» №6(60). DOI:10.32743/UniChem.2019.60.6/ 17-21стр 17. ME Eshkobilova, IE Abdurakhmanov, AM Nasimov/Some metrological characteristics of a semiconductor methane sensor/ SamSU scientific Bulletin/ 136-140 стр 18. Абдурахманов Э Сиддикова Х.Г., Эшкобилова М.Э Термокаталитический сенсор для селективного мониторинга природного газа/ International scientific conference Globalscience and innovations/ С.235-238

19. Толибов А. А Шукурова Д. Б Абдурахмонов Э Эшкобилова М. Э Эгамов У. Б / МЕТАННИ АНИҚЛОВЧИ ТЯГ-CН4 ГАЗ АНАЛИЗАТОРИНИНГ МЕТРОЛОГИК ТАВСИФЛАРИГА ТУРЛИ ОМИЛЛАРНИНГ ТАЪСИРИ/ RESEARCH FOCUS | VOLUME 2 | ISSUE 11 | 2023 ISSN: 2181-3833 20. Абдурахманов Э. Абдурахманов И.Э., Сидикова Х.Г., Эшкобилова М.Э., Насимов А.М., Мурадова З./ Разработка сенсора и сигнализатора непрерывного контроля СН4 для систем автоматизированного микроклимата/ Science and education. Scientific journal. ISSN 2181-0842 Volume 1, issue 1.

Iqtiboslar dinamikasi

ReLibrary iqtiboslari

ReLibraryTekshirilgan Metodologiya

Kim iqtibos qilgan4

ReLibrary’da chop etilgan va ushbu yozuvga iqtibos keltirgan ilmiy ishlar, yangisi yuqorida.

  1. THYROID DISEASE HASHIMOTO‘S THYROIDITIS CLINICAL SIGNS AND EXAMINATION BY ULTRASOUND METHODS.

    Yo‘ldosheva Gulsara Bahridinovna, Ro‘zimurodova Sarvinoz Dilmurod qizi, Tursunpo‘latova Dilbar Talatjon qizi va boshqalar · Research Focus International Scientific Journal · 2025

  2. JIGAR VA O‘T YO‘LLARI KASALLIKLARINI ULTRATOVUSH TEKSHIRUV USULLARI ORQALI BAHOLASH

    Yo‘ldosheva Gulsara Bahridinovna, Abduxoliqova Gavhar Abdurasul gizi, Utemurotov Oybek Ravshanbek uli va boshqalar · Research Focus International Scientific Journal · 2025

  3. DEVELOPMENT OF IONOPHORES FOR ION-SELECTIVE ELECTRODES FOR THE DETERMINATION OF MEDICINAL SUBSTANCES.

    Ulug‘murotova Gulhayo Shuhrat qizi, Abdurahmonova Z. E. · Research Focus International Scientific Journal · 2025

  4. CREATION OF CHEMICAL SENSORS AND ALARMS TO ENSURE EXPLOSION AND FIRE SAFETY OF DOMESTIC AND INDUSTRIAL FACILITIES

    Ibodova Sabrina Erkin qizi, Erdanov Fazliddin Faxritdinovich, Eshkobilova M.E · Research Focus International Scientific Journal · 2025

Adabiyotlar20 ta adabiyot

  1. Smith, J., & Patel, A. (2023). Demographic and Clinical Profile of Chronic Myeloid Leukemia Patients in a Resource-Limited Setting: A Comprehensive Analysis. Journal of Oncology Research, 8(4), 210-225. doi:10.1234/jor.2023.1234510.1234/jor.2023.12345
  2. Johnson, L., & Garcia, M. (2024). Challenges in Managing Chronic Myeloid Leukemia in Resource-Limited Healthcare Settings: Insights from Clinical Data. International Journal of Hematology, 12(2), 80-95. doi:10.5678/ijh.2024.2345610.5678/ijh.2024.23456
  3. Williams, K., & Nguyen, Q. (2023). Epidemiological Trends and Treatment Patterns of Chronic Myeloid Leukemia Patients in Resource-Constrained Environments. Journal of Global Oncology, 5(3), 150-165. doi:10.1200/jgo.2023.3456710.1200/jgo.2023.34567
  4. Brown, R., & Khan, S. (2024). Impact of Socioeconomic Factors on Chronic Myeloid Leukemia Management: A Study in Resource-Limited Settings. Journal of Health Economics and Outcomes Research, 7(1), 45-60. doi:10.3578/jheor.2024.4567810.3578/jheor.2024.45678
  5. Martinez, E., & Wang, Y. (2023). Optimizing Treatment Strategies for Chronic Myeloid Leukemia Patients in Low-Resource Healthcare Settings: A Retrospective Analysis. Journal of Clinical Oncology, 10(5), 220-235. doi:10.1200/jco.2023.5678910.1200/jco.2023.56789
  6. Wilson, T., & Kim, D. (2024). Gender Disparities in Chronic Myeloid Leukemia Management: Insights from Resource-Limited Settings. Journal of Gender Studies in Oncology, 3(2), 75-90. doi:10.1002/jgo.2024.1234510.1002/jgo.2024.12345
  7. Garcia, A., & Li, Q. (2023). Molecular Profiling of Chronic Myeloid Leukemia Patients in Resource-Limited Healthcare Settings: Implications for Treatment. Blood Advances, 6(7), 310-325. doi:10.1182/bloodadvances.2023.8901210.1182/bloodadvances.2023.89012
  8. Nguyen, T., & Hernandez, R. (2024). Challenges and Opportunities in CML Management: Lessons from Resource-Limited Settings. Journal of Cancer Policy, 9, 40-55. doi:10.1016/j.jcpo.2024.6789010.1016/j.jcpo.2024.67890
  9. Patel, S., & Martinez, L. (2023). Tailoring Treatment Strategies for Chronic Myeloid Leukemia Patients Based on Age and Disease Phase in Resource-Constrained Environments. Cancer Management and Research, 15, 180-195. doi:10.2147/cmar.2023.4567810.2147/cmar.2023.45678
  10. Kim, Y., & Jones, P. (2024). Addressing Healthcare Challenges in Chronic Myeloid Leukemia: Insights from a Resource-Limited Setting. Journal of Oncology Practice, 10(4), e178-e192. doi:10.1200/jop.2024.0123410.1200/jop.2024.01234
  11. АЭ Эшкобилов Ш.А., Эшкобилова М.Э. Определение природного газа в атмосферном воздухе и технологических газах Журнал «Экологические системы и приборы» 9 (2015), С.11-14.
  12. FF Kholmirzayev, ME Eshkobilova, DM Urokov, E Abdurakhmanov The influence of temperature on the sensitivity of a semiconductor methane sensor/ Materials of the Republican conference" Development of analytical chemistry in Uzbekistan”. Tashkent 78-81стр
  13. Sh.Pardaeva E.Abdurakhmanov M Eshkabilova, N Muminova , Kh Sidikova/Template Synthesis of Nanomaterials based on Titanium and Cadmium Oxides by the Sol-Gel Method, Study of their Possibility of Application As A Carbon Monoxide Sensor (II)/ Journal of Pharmaceutical Negative Results ¦ Volume 13 ¦ Special Issue 3 ¦ 2022/ 1343-1350 стр
  14. E Abdurakhmanov, ZB Murodova, ME Eshkobilova, Kh G Sidikova/Development of a selective sensor for the determination of hydrogen/ IOP Conference Series: Earth and Environmental Science
  15. Sidikova Xulkar Gulomovna, Eshkobilova Mavjuda Ergashboyevna, Abdurakhmanov Ergashboy/Range of measuring of base error of selective thermocatalytical sensor on methane/ European science review/ 140-143 стр10.29013/esr-20-1.2-140-143
  16. Насимов А.М Эшкобилова М.Э./Газоанализатор (ТПГ-СН4) для мониторинга метана на основе термокаталитических и полупроводниковых сенсоров/ Журнал «Universum: химия и биология» №6(60). DOI:10.32743/UniChem.2019.60.6/ 17-21стр10.32743/unichem.2019.60.6/
  17. ME Eshkobilova, IE Abdurakhmanov, AM Nasimov/Some metrological characteristics of a semiconductor methane sensor/ SamSU scientific Bulletin/ 136-140 стр
  18. Абдурахманов Э Сиддикова Х.Г., Эшкобилова М.Э Термокаталитический сенсор для селективного мониторинга природного газа/ International scientific conference Globalscience and innovations/ С.235-238
  19. Толибов А. А Шукурова Д. Б Абдурахмонов Э Эшкобилова М. Э Эгамов У. Б / МЕТАННИ АНИҚЛОВЧИ ТЯГ-CН4 ГАЗ АНАЛИЗАТОРИНИНГ МЕТРОЛОГИК ТАВСИФЛАРИГА ТУРЛИ ОМИЛЛАРНИНГ ТАЪСИРИ/ RESEARCH FOCUS | VOLUME 2 | ISSUE 11 | 2023 ISSN: 2181-383310.66073/researchfocus.v2i11.589
  20. Абдурахманов Э. Абдурахманов И.Э., Сидикова Х.Г., Эшкобилова М.Э., Насимов А.М., Мурадова З./ Разработка сенсора и сигнализатора непрерывного контроля СН4 для систем автоматизированного микроклимата/ Science and education. Scientific journal. ISSN 2181-0842 Volume 1, issue 1.

Metama’lumot

Identifikator
REL-A-013650
Nashr sanasi
2024-06-05
Til
inglizcha
Jurnal
Research Focus International Scientific Journal
Jild
3
Son
5
DOI
10.66073/researchfocus.v3i5.2714
ISSN
2181-3833 · 2181-3833
Nashriyot
LLC Ilm-fan va innovatsiyalar akademiyasi
Sahifa
191–196
Litsenziya
Ushbu ilmiy ish CC BY 4.0 litsenziyasi asosida ochiq.
Ko‘rishlar
42026-10-10 dan beri o‘lchanmoqda
Metadata manbasi
Research Focus International Scientific Journal
Oxirgi yangilanish
2026-09-11